Estimators of glomerular filtration rate (GFR) have been shown to be flawed in critically ill patients, especially for augmented renal clearance (ARC), commonly defined as a measured urinary creatinine clearance (CrCl) ≥ 130 ml/min/1.73 m^2^ \[[@CR1]\]. Therefore, measuring CrCl should be performed in daily practice on the intensive care unit (ICU). However, many ICUs still rely on estimating formulae to monitor GFR \[[@CR1], [@CR2]\]. As estimators underestimate measured CrCl in ARC patients, ARC might remain unrecognized and lead to subtherapeutic plasma levels of drugs with predominant renal clearance \[[@CR3]\]. Therefore, the aim of this study is to define the most precise GFR estimator, which can then be used to detect ARC when measured CrCl is unavailable.

We performed a multicenter retrospective registry-based \[[@CR4]\] cohort study in adult ICUs from 3 tertiary university-affiliated hospitals in Belgium (Leuven, Ghent, Antwerp). All consecutive patients admitted between January 2013 and December 2015 were screened for eligibility. All patients ≥ 18 years old and having at least one measured 24-h urinary CrCl (CrCl~24h~) were included. Agreement between CrCl~24h~ and formulae estimating renal function, i.e., Cockcroft--Gault (CG), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), and Modification of Diet in Renal Disease Study (MDRD), was evaluated on all included ICU days. For the estimator with the best precision, a cut-off for ARC with optimal specificity and sensitivity was identified, by calculating the Youden index \[[@CR5]\]. Predictions for ARC using the cut-off value were compared to the actual presence of ARC based on the CrCl~24h~. Cut-off values with either very high sensitivity (\> 95%) or specificity (\> 95%) were also identified. Finally, the performance of these cut-offs was evaluated in an external single-center (Leuven, January 2016--December 2016) validation set by receiver-operating characteristics (ROC) curve analysis, using 2000 bootstrap replicates. The same inclusion and exclusion criteria as described above were applied.

A total of 51,604 ICU days were included to define a cut-off. Agreement analysis between CrCl~24h~, the clinical reference, and the formulae estimating renal function is shown in Table [1](#Tab1){ref-type="table"}. None of the estimators were precise (i.e., standard deviation of the mean bias was large for all estimators), with the CKD-EPI formula performing best over the whole CrCl~24h~ range, and for ARC specifically, as illustrated in Fig. [1](#Fig1){ref-type="fig"}a. Hence, the CKD-EPI formula was selected for further analysis. In the validation set, 10,503 ICU days were included. For the CKD-EPI formula, the optimal cut-off for ARC was 96.5 ml/min/1.73 m^2^. This cut-off showed a sensitivity of 86.6% \[85;88.1\] and a specificity of 71% \[70;71.9\]. The cut-off values with very high sensitivity and specificity were 87.3 ml/min/1.73 m^2^ (sens, 95.8% \[95;96.7\]; spec, 57.6% \[56.6;58.7\]) and 125.2 ml/min/1.73 m^2^ (sens, 31.4% \[29.4;33.5\]; spec, 95.2% \[94.7;95.6\]), respectively. The ROC curve analysis including the cut-off values is shown in Fig. [1](#Fig1){ref-type="fig"}b. Evaluating the optimal cut-off in the validation set, we found that the proportion of accurate predictions for ARC decreased during the first 2 weeks of ICU stay. The is due to an increased false positive rate (Day-1, 16%; Day-14, 49%). Table 1Agreement analysis between CrCl~24h~ and formulae estimating renal functionAll ICU days (*n* = 51,604)CrCl~24h~ \< 130 ml/min/1.73 m^2^ (*n* = 41,290)CrCl~24h~ ≥ 130 ml/min/1.73 m^2^ (*n* = 10,314)Median (IQR) (ml/min/1.73 m^2^) CrCl24h73 (37;118)58 (30;88)166 (145;200) CrCl~CG~83 (50;127)70 (43;103)145 (116;183) eGFR~MDRD~87 (50;130)72 (42;109)143 (115;185) eGFR~CKD-EPI~88 (51;108)75 (43;99)116 (104;130)Correlation with CrCl~24h~ = Spearman correlation coefficient CrCl~CG~0.63°0.62°0.18° eGFR~MDRD,~0.59°0.60°0.15° eGFR~CKD-EPI~0.69°0.72°0.19°Mean bias (95% CI) = mean difference CrCl~24h~ -- estimator (ml/min/1.73 m^2^) CrCl~CG~− 11 (− 11;-10)− 20 (− 20;-19)25 (23;27) eGFR~MDRD~− 14 (− 15;− 14)− 23 (− 23;− 23)21 (19;23) eGFR~CKD-EPI~3 (3;4)− 12 (− 13;− 12)66 (64;67)Precision = SD of the bias (ml/min/1.73 m^2^) CrCl~CG~554183 eGFR~MDRD~614694 eGFR~CKD-EPI~48\*26\*62\*Accuracy = percentage within 30% of CrCl~24h~ CrCl~CG~474558 eGFR~MDRD~454356 eGFR~CKD-EPI~505145*n* number of ICU days; *CrCl*~*24h*~ creatinine clearance measured by 24-h urine collection, corrected for body surface area; *IQR* interquartile range; *CrCl*~*CG*~ estimated creatinine clearance by the Cockcroft -- Gault formula, corrected for body surface area; *eGFR*~*MDRD*~ estimated glomerular filtration rate by the 4-variable Modification of Diet in Renal Disease formula; *eGFR*~*CKD-EPI*~ estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration formula; *SD* standard deviation; *CI* confidence interval°*p* \< 0,001\*Best performingFig. 1**a** Bias in function of CrCl~24h~ for the three formulae estimating renal function. Top: MDRD (ml/min/1.73 m^2^); mid: CG corrected for a body surface area of 1.73 m^2^ (ml/min/1.73 m^2^); bottom: CKD-EPI (ml/min/1.73 m^2^). **b** Receiver operating characteristics curve analysis for the CKD-EPI formula. The shaded area represents the 95% confidence intervals. The dots represent the cut-off values for optimized sensitivity and specificity, very high (\> 95%) sensitivity and very high (\> 95%) specificity

Overall, there was poor agreement between CrCl~24h~ and GFR estimators, confirming previous literature \[[@CR1]\]. However, the CKD-EPI formula, which is the "least worse" alternative to CrCl~24h~, provided a cut-off with reasonable performance to detect ARC. Depending on the clinical context, this cut-off can be adapted to increase sensitivity or specificity. When applying this cut-off, the user should note that the accuracy decreases over time during the first 2 weeks of ICU stay. Hence, its largest benefit lies in the beginning of ICU stay. The presented CKP-EPI cut-off can be used to guide upfront increased antimicrobial dosing in patients presenting with ARC early upon ICU admission, when CrCl~24h~ is not available.
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:   Measured 24-h urinary creatinine clearance

CG
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:   Chronic Kidney Disease Epidemiology Collaboration formula

MDRD

:   Modification of Diet in Renal Disease Study formula

Trial registration: The study was registered at ClinicalTrials.gov, NCT03954275.
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